Citations

Clear

248 citation(s) found for "Bhatt, S".

RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
Gangat, Naseema, Tefferi, Ayalew, Hexner, Elizabeth O., Michaelis, Laura C. , Gerds, Aaron Thomas, Jain, Akriti G., Islam, Prioty , Rampal, Raajit, Swords, Ronan T., Pettit, Kristen M., Bhatt, Sima, Buch, Akshay, Pelletier, Olivia, Savage, Will, Gangat, Naseema , Tefferi, Ayalew , Bose, Prithviraj , Hexner, Elizabeth O. , Gerds, Aaron T. , Jain, Akriti Gupta , Rampal, Raajit K. , Swords, Ronan , Talpaz, Moshe , Pettit, Kristen , Buch, Akshay, Pelletier, Olivia, Savage, Will, Halpern, Anna B.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 6501-6501

10.1200/jco.2026.44.16_suppl.6501 Get It

6501 Background: Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelofibrosis (MF) and anemia. Chronic hepcidin elevation limits iron availability for red blood cell (RBC) production and contributes to anemia onset and severity. DISC-0974 is an investigational, first-in-class, monoclonal antibody that blocks hemojuvelin, a co-receptor in the bone morphogenetic protein-signaling pathway driving hepcidin expression. Methods: RALLY-MF (NCT05320198) is an ongoing Phase 2, open-label study conducted in the US. The primary aim is to evaluate DISC-0974 efficacy in participants with MF and anemia. Secondary aims include evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD). Eligible participants are ≥18 years of age with primary or secondary MF and hemoglobin (Hgb) <10 g/dL or RBC transfusion requirement. Participants enroll into 3 cohorts based on RBC units transfused in the 84 days prior to screening: non-transfusion dependent (nTD, 0 units and Hgb <10 g/dL), low transfusion burden (TD low, 1-2 units), high transfusion burden (TD high, 3-12 units). Stable dose of concomitant Janus kinase inhibitor (JAKi) is allowed. DISC-0974 is administered subcutaneously at 50 mg monthly for up to 6 doses, with escalation to 75 mg for inadequate or lost response. Primary endpoints include major hematologic response defined as transfusion independence (TI) during any consecutive 16 weeks (TD low) or 12 weeks (TD high), or a mean Hgb increase of ≥1.5 g/dL from baseline for ≥12 weeks (nTD). Secondary endpoints include PK/PD markers of iron regulation and safety assessments. Data were summarized using descriptive statistics. Results: At data cut (16 Oct 2025), 47 participants enrolled in the nTD (n=30), TD low (n=10), and TD high (n=7) cohorts, with 53% on concomitant JAKi therapy. DISC-0974 led to sustained hepcidin reduction and iron mobilization across cohorts. DISC-0974 resulted in meaningful hematologic responses among evaluable participants: 50% of nTD participants achieved a mean Hgb increase of ≥1.5 g/dL for ≥12 weeks, 71% of TD low participants achieved TI for ≥16 weeks, and 67% of TD high participants experienced a ≥50% reduction in transfusion burden, with follow-up ongoing. Major hematologic response rates were 50% for participants on and off concomitant JAKi therapy (n=18 and n=16, respectively). DISC-0974 was associated with meaningful improvement in FACIT-Fatigue scores for nTD and TD low participants. Serious adverse events (AEs, n=9) and ≥Grade 3 AEs (n=16) were considered unrelated to DISC-0974. There were no early withdrawals due to AEs. Conclusions: DISC-0974 was well tolerated and shows a favorable safety profile. Anemia response and fatigue scores improved across patients with MF and anemia, including those receiving JAKi therapy. These data validate hepcidin reduction as a promising approach to treating anemia in MF. Clinical trial information: NCT05320198 .
C27-15 Clinical Features Enhance the Performance of Radiomics Model in Differentiating Coccidioides From Malignant Pulmonary Nodules in Southwestern United States
Biondi, M V, Bhatt, S, Hamad, A, Ahmed, M, Ellis, D, Vergara, A Diaz Arumir, Rajagopalan, S, Jokerst, C, Bartholmai, B J, Peikert, T, Varghese, C, VERGARA, ALEJANDRO DIAZ ARUMIR, Rajagopalan, Srinivasan , Bartholmai, Brian J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4417 Get It

Abstract Rationale In fungal endemic regions, differentiating benign from malignant pulmonary nodules on CT scans remains a major diagnostic challenge. Coccidioides nodules frequently resemble malignant lesions on CT and PET imaging, presenting significant challenges for differentiation, even among radiologists. Consequently, the benign biopsy and resection rate, especially in the Southwestern US, remains high. We previously developed [DOI:10.1371/journal.pone.0196910] and externally validated [DOI:10.1183/13993003.02485-2020] the Benign versus aggRessive nODule Evaluation using Radiomic Stratification (BRODERS) machine learning (ML) classifier to non-invasively distinguish between benign and malignant pulmonary nodules with an AUC of 0.87. However, its performance in certain benign nodules with malignant surface and texture characteristics like in coccidioidomycosis had a suboptimal AUC of 0.65. In this study, we redesigned our radiomics model by including numerous clinical features. Methods In this retrospective study, 113 pulmonary nodules (66 Coccidioides and 47 adenocarcinoma spectrum) detected on CTs with ground truth pathology diagnosis were identified by screening for key terms like “nodule”, “cocci”, and “adenocarcinoma” from both CT and pathology reports using a large language model trained on clinical textual data (Illuminate®). Clinical features such as demographics, smoking history, and laboratory studies were extracted by trained clinicians from the electronic medical record. All nodules were segmented and radiomic features extracted using a semi-automated seed growing algorithm previously described [DOI: 10.1097/JTO.0b013e3182843721]. The database was randomly split into an 80%-20% development and hold-out set prior to ML modeling. Feature selection for variables was conducted utilizing Elastic Net Regression, which provides a balanced approach between Lasso and Ridge regression. A logistic regression model was developed using the selected features and ground truth information of the training cohort. The true performance of the model was tested on the hold-out set. Results 160 radiomics and 22 clinical features were extracted. Elastic Net regression identified 44 features that contributed the most. Some of these clinical features include presence of satellite lesions, smoking history, and presence of positive IgG coccidiomycosis serology. The AUC of the ROC curve for the hold-out test set was 0.86. Conclusions The clinical features of significance that emerged during multimodal modeling are explainable. Designing explainable ML models is important, especially in the Southwestern US where Coccidioides nodules can appear to be malignant to both human experts and ML models. Although coccidioidomycosis serologies alone lack sensitivity and specificity to diagnose Coccidioides nodules, integrating them with a multimodal ML model can improve differentiation between benign Coccidioides and malignant adenocarcinoma nodules. This abstract is funded by: None
D22-22 Neighborhood-level Disparities Among Patients With IPF
Bhatt, S, Gyimah, C, Helfinstine, D, Dempsey, T M, Limper, A H, Gyimah, C, Helfinstine, David A. , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2839 Get It

Abstract Rationale Patients with idiopathic pulmonary fibrosis (IPF) living in disadvantaged neighborhoods have worse composite outcomes and pulmonary function. Although the current FDA approved drugs reduce lung function decline and may improve mortality for this progressive and fatal disease, equitable access to therapy remains a challenge, which may be contributing to low antifibrotic uptake. Existing understanding of social determinants of health in IPF is derived from local registries and special subpopulations, such as Veterans. The aim of our study is to investigate the association between neighborhood-level deprivation indicators and both the distribution of patients with IPF and outcomes in a large national database. Methods We performed a retrospective cohort analysis between October 1st, 2014, and December 31st 2022, using the Optum Labs Data Warehouse, a large de-identified administrative claims database. We used claims data from commercial, Medicare Advantage, and Medicare Fee-for-Service enrollees across the United States. Diagnosis of IPF was defined using ICD-9 and ICD-10 codes. Social deprivation index (SDI), assessed at the zip code tabulation area level, was determined based on 7 demographic characteristics from the 2015-2019 American Community Survey. Patients were grouped in quintiles based on SDI at diagnosis, where higher values reflect greater deprivation. Hazard ratios (HR) were calculated for all-cause mortality as primary and hospitalization as secondary outcome. Results A total of 96,143 patients (mean age 75.1 years ± 6.9 years) were included in the study, 23.5% received antifibrotics. As area deprivation increased, proportion of female, Black, and Hispanic patients increased, whereas, proportion of male, White, and Asian patients decreased. Similarly, antifibrotic use declined slightly, while prescription of steroids and oxygen increased with SDI. Residing in most disadvantaged neighborhoods increased risk of hospitalization (HR, 1.13 [95% CI 1.09 - 1.17] and all-cause mortality (HR, 1.15 [95% CI 1.11 - 1.19]) after adjusting for covariates over median follow-up of 301 days and 680 days, respectively. Conclusion Gender and racial disparities were evident among IPF patients who live in resource-limited areas. Our study shows that greater proportion of female, Black, and Hispanic IPF patients were disproportionately represented in more socioeconomically deprived areas. Furthermore, as area-level disadvantage increased, fewer patients received antifibrotics, while more patients were on steroids and oxygen therapy potentially indicating more advanced disease. Moreover, living in disadvantaged neighborhoods was associated with worse all-cause mortality and hospitalizations. Identifying individuals who live in socioeconomically disadvantaged areas is essential to provide equitable care and improve outcomes for this life-threatening disease. This abstract is funded by: None
A39-18 Ezetimibe Associated With Improved Outcomes in Patients With Idiopathic Pulmonary Fibrosis
Gyimah, C, Bhatt, S, Helfinstine, D, Dempsey, T M, Limper, A H, Bhatt, S, Helfinstine, David A. , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2242 Get It

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrosing interstitial lung disease that continues to have high morbidity and mortality. There are only 3 approved medications, (nintedanib, pirfenidone and nerandomilast) which marginally slow FVC decline and only nerandomilast having some mortality benefit. All three have no effect on quality of life (exacerbations and hospitalizations). There is an urgent need to find more effective treatment options. Since IPF is predominantly a disease of the elderly with a peak prevalence in those 65 and older, it is common for these individuals to have other comorbidities such as Hyperlipidemia (HLD). Interestingly, in a prior small study of IPF patients, there is evidence to suggest clinical benefit from ezetimibe, a medication used to treat HLD. This study aims to further evaluate the clinical benefits of ezetimibe in patients with IPF in a large national cohort. Methods We conducted this study using the Optum Labs Data Warehouse (OLDW). The OLDW contains de-identified administrative claims data, including medical and pharmacy claims and enrollment records. This study used claims data from commercial, Medicare Advantage (MA), and Medicare Fee-for-service (FFS) enrollees between October 1st, 2014, and December 31st, 2021. Diagnosis of IPF was defined using ICD-9 and ICD-10 codes. Patients without a diagnosis of IPF were excluded. P &lt; 0.05 was set to determine statistical significance. Two matched patient cohorts depending on ezetimibe use were defined. Primary outcome was all-cause mortality, and secondary outcome was hospitalizations. Results We identified 7724 patients with IPF. After adjusting for age, age group, gender, race, health plan, year of IPF diagnosis, smoking, diabetes, statin treatment, and antifibrotic treatment, two cohorts were identified and matched, patients treated with ezetimibe (n = 3862) and patients not treated with ezetimibe (n = 3862). Among the patients with IPF treated with ezetimibe, ezetimibe use was associated with a reduction in all-cause mortality (hazard ratio [95% CI]: 0.704 [0.660 - 0.752], p-value: &lt;0.001) and hospitalizations(hazard ratio [95% CI]: 0.907 [0.857 - 0.959], p-value: 0.001) compared to patients not treated with ezetimibe. Conclusion In patients with IPF, treatment with ezetimibe may be associated with improved clinical outcomes. Further studies are necessary to confirm benefits, assess anti-fibrotic effects, and inform implementation in management of IPF. As IPF remains a disease with limited treatment options, repurposing drugs continues to offer an avenue to find affordable, safe and already approved medications for use. This abstract is funded by: None
B102-02 Deep Learning-based Detection of Homozygous Alpha-1 Antitrypsin Deficiency From HRCT: A Proof-of-concept Study Across COPDGene, SPIROMICS, and GRADS Cohorts
Tejwani, V, Hatt, C R, Barjaktarevic, I, Bhatt, S P, Bowler, R P, Drummond, M B, Han, M K, Hersh, C P, Ortega, V E, Serban, K A, Stoller, J K, Washko, G R, Wells, J M, Yadav, R, Strange, C, Siddharthan, T, Wells, J. Michael , Wells, J Michael , Hatt, Charles R. , Bhatt, Surya P. , Han, MeiLan King , Hersh, Craig P. , Serban, Karina A. , Stoller, James K. , Strange, C, Siddharthan, T

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1900 Get It

Abstract Rationale Alpha-1 antitrypsin deficiency (AATD) continues to be underdiagnosed. The estimated prevalence of the most common severe deficient genotype, PI*ZZ, is ∼1:3500 or 100,000 Americans but only ∼10,000 such individuals have been recognized. Diagnostic delays persist and these delays are associated with worse disease. High-resolution CT (HRCT) imaging may contain latent phenotypic AATD signatures that are not visibly apparent to clinicians. We hypothesized a deep learning model could identify imaging patterns predictive of AATD from inspiratory HRCT scans. Methods Confirmed genotypes and HRCT scans were pooled from COPDGene, SPIROMICS, and GRADS, yielding 350 MM, 102 MZ, and 69 ZZ participants. Only scans reconstructed with smooth kernels (GE STANDARD, Philips B, Siemens B31f/B35f) and slice thickness &lt; =1.25mm were used. The cohort was selected to have similar distributions of quantitative emphysema, sex, and age by matching five MZ and two MM subjects to each ZZ subject (&lt;10-year age difference, same sex, and &lt;3% difference in %LAA). Tobacco smoke-exposure was more prevalent among the MM/MZ groups given these were predominantly from the tobacco smoke-enriched COPDGene and SPIROMICS cohorts. A DenseNet121 convolutional neural network (CNN) was trained using the MONAI platform to predict genotype by outputting probabilities for MM, MZ, and ZZ. Input to the CNN was a three-channel LAA-910, LAA-950, and LAA-970 map downsampled to 2.0mm3 resolution to remove bias due to differences in scanner and image reconstruction parameters. Five-fold cross-validation was performed. Area under the curve (AUC) was calculated for classification of ZZ vs other genotypes (MM/MZ) and MZ vs MM, with statistical significance assessed at p &lt; 0.05. Results The three groups were similar across age (mean±SD years: MM 57.9±8.8, MZ: 57.5±8.9, ZZ: 55.0±10.7), sex (% female: MM: 48.2%, MZ: 46.7%, ZZ: 47.6), and emphysema (LAA-950%: MM: 13.0±12.2, MZ: 12.4±11.8, ZZ: 13.1±11.9). There was a higher prevalence of ever smokers among MM (100%) and MZ (91.7%), compared to ZZ (47.6%). The model achieved an AUC of 0.806 (p &lt; 0.001) for classification of ZZ vs other genotypes, demonstrating robust discriminatory ability for homozygous AATD. Classification of MZ vs other genotypes did not achieve an AUC significantly greater than 0.5. Conclusions This proof-of-concept study demonstrates that deep learning applied to routine inspiratory HRCT can accurately identify homozygous AATD. These findings support the potential role of imaging-based machine learning as a non-invasive screening tool for undiagnosed ZZ individuals. Future work will focus on cohort enrichment, integration with clinical parameters, and explainability of model-derived imaging features. This abstract is funded by: NIH NHLBI K23HL173570
Drug Repurposing for Lung Disease: Mechanistic Rationale, Clinical Evidence, and the Path Forward
Bhatt, Shubhang K, GYIMAH, CLAUDIA, Kaul, Bhavika , Limper, Andrew, Dempsey, Timothy, Limper, Andrew H. , Limper, Andrew H , Bhatt, S, Gyimah, Claudia , Johannson, Kerri A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag216 | PMID 42089679 Get It

An automated plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease
Levin, Scott , Engel, Brian, Carlson, Corey M., Hinson, Jeremiah, Holland, Mark D. , Figdore, Dan, Tiers, Laurent, Bhatt, Kinal , Schlichtmann, Ben, Hoffmann, Katie, Bae, Ye Eun, Szabo, Miklos, Um, Yoo Hyun , Algeciras-Schimnich, Alicia, Hinson, Jeremiah S. , Figdore, Daniel J. , Lim, Hyun Kook , Schlichtmann, Benjamin W. , Lehmann, Sylvain , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | March 8, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71143 | PMID 41789706 Get It

Abstract INTRODUCTION Determining apolipoprotein E ( APOE ) ε4 allele status, a key genetic risk factor for Alzheimer's disease (AD), requires molecular genotyping infrastructure not widely accessible beyond specialized centers. METHODS A fully automated high‐throughput apoE E4 proteotyping immunoassay was evaluated for clinical performance (460 participants across three cohorts) and analytical validity. Concordance with polymerase chain reaction (PCR)‐based genotyping and measures of analytical validity were reported. RESULTS The apoE E4 immunoassay demonstrated 99.6% (95% confidence interval [CI]: 98.4% to 99.9%) concordance with PCR‐based APOE ε4 genotype results across the pooled clinical cohort; 100.0% (95% CI: 97.1% to 100.0%) in those with AD ( N = 127) and 99.4% (95% CI: 97.8% to 99.8%) in those without AD (333). The assay met analytical validity criteria for E4 isoform specificity, interference, precision, and stability. DISCUSSION The apoE E4 immunoassay demonstrated high concordance with PCR‐based genotyping and robust analytical validity, offering an accessible alternative for APOE ε4 zygosity assessment. Highlights A novel high‐throughput plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification was developed and evaluated for clinical performance and analytical validity. The apoE E4 immunoassay demonstrated high concordance (99.6%) with PCR‐based APOE ε4 genotyping across a diverse international cohort, and a robust analytical profile. An apoE E4 immunoassay may offer a more cost‐effective and accessible alternative to DNA genotyping approaches currently used for AD risk evaluation and anti‐amyloid treatment decisions.
Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study
Wirbel, Jakob , Saber, Wael, Andermann, Tessa M, Fei, Teng , Brooks, Erin F. , Doyle, Boryana , Pincus, Nathan B. , Bar, Merav , Bolaños-Meade, Javier, Chhabra, Saurabh, Choi, Sung Won , Clark, William, Elmariah, Hany, Jones, Richard J. , Jp, Levine, Logan, Brent R, Malki, Monzr M Al, Rashidi, Armin, Rezvani, Andrew R. , Riches, Marcie L., Runaas, Lyndsey, Sandhu, Karamjeet , Spahn, Ashley, Horowitz, MM, Hamadani, Mehdi, Kean, Leslie S. , Perales, Miguel-Angel, Bhatt, Ami S. , Choi, Sung Won , Elmariah, Hany , Andermann, Tessa M. , Saber, Wael , Martens, Michael J , Peled, Jonathan U , Andermann, Tessa M , Fei, Teng , Brooks, Erin F , Doyle, Boryana , Pincus, Nathan B , Jenq, Robert R , Bar, Merav , Bratrude, Brandi , Chhabra, Saurabh , Elmariah, Hany , Gooptu, Mahasweta , Holtan, Shernan , Al Malki, Monzr M , Murthy, Hemant S , Rashidi, Armin , Rezvani, Andrew R , Sung, Anthony D , van den Brink, Marcel R M , Kean, Leslie S , Perales, Miguel-Angel , Bhatt, Ami S , Choi, Sung Won , Saber, Wael , Martens, Michael J. , Peled, Jonathan U. , Jenq, Robert R. , Bolaños‐Meade, Javier , Clark, William, Das, Suman R. , Holtan, Shernan G. , Logan, Brent R. , Malki, Monzr M. Al , Murthy, Hemant S. , Rashidi, Armin , Riches, Marcie , Sung, Anthony D. , Hamadani, Mehdi , Perales, Miguel‐Angel

Mayo Clinic

No container title available | February 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.19.706769 | PMID 41756883 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for many hematological malignancies, but graft-versus-host disease (GVHD) is a common complication. Low gut microbiome diversity is associated with higher GVHD risk and shorter survival in multiple studies. Recently, the BMT CTN 1703 clinical trial demonstrated superiority of a GVHD-prophylaxis regimen including post-transplant cyclophosphamide (PTCy) compared to the standard prophylaxis (tacrolimus and methotrexate, Tac/MTX) in terms of GVHD-free, relapse-free survival at one year among reduced intensity conditioning allo-HCT recipients. However, the effect of PTCy on the gut microbiome and its association with clinical outcome have not been described. Here, we report on a companion randomized clinical controlled trial (BMT CTN 1801), which collected 2575 longitudinal stool samples from 304 study participants. Samples were obtained up to weekly up to day 84 post allo-HCT and at less frequent intervals thereafter, up to 2 years. Microbiome diversity and absolute microbial load were lower in the PTCy group compared to the Tac/MTX group on days 14–28 post-HCT. However, diversity at the timepoint closest to neutrophil engraftment was not significantly associated with non-relapse mortality after one year or other clinical outcomes, contrary to expectations from previous studies. Microbial domination events, when a single species exceeds 30% relative abundance, were comparable across treatment arms and reflected both pathogen blooms as well as less severe disruptions of the microbial community. Clostridium scindens and secondary bile acid metabolism pathways were less prevalent in the PTCy arm than in the Tac/MTX arm post-HCT, yet presence of secondary bile acid metabolism pathways was associated with a lower risk of chronic GVHD. Given that PTCy was associated with a greater disruption of the microbiome as measured by diversity, absolute microbial abundance, and bile acid metabolism capability, but better clinical outcomes overall, these data suggest that the importance of the microbiome in modulating the host immune systems after allo-HCT is specific to different types of GVHD prophylaxis.
Prevalence of Intracranial and Cervical Artery Abnormalities in Patients with Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders Presenting to an Academic Headache Clinic
Rozen, Todd D. , Rozen, Ethan M., Wilson, Frances C., Shields, Raymond C., Hayes, Sharonne N., Knight, Dacre R. T., Gajarawala, Shilpa N., Sandhu, Sukhwinder J.S., Bhatt, Alok A. , Fairweather, DeLisa, Hayes, Sharonne N. , Fairweather, DeLisa , Sandhu, Sukhwinder J.S. , Knight, Dacre , Wilson, Frances C , Hayes, Sharonne N , Knight, Dacre R T , Gajarawala, Shilpa , Sandhu, Sukhwinder S , Bhatt, Alok A , Fairweather, DeLisa , Rozen, Todd D. , Bruno, Katelyn A. , Tweet, Marysia S.

Mayo Clinic

Neurology International | February 11, 2026 | Volume: 18 | Issue: 2 | Pages: 33

10.3390/neurolint18020033 | PMID 41745718 Get It

Background/Objective: It remains unknown whether patients with the more common forms of hypermobility carry an elevated risk for the development of intracranial/cervical artery abnormalities. The objective of this study was to determine the prevalence of unruptured intracranial aneurysms, spontaneous cervical artery dissections, and fibromuscular dysplasia in patients with hypermobile Ehlers–Danlos Syndrome (hEDS) and hypermobility spectrum disorders (HSD) who presented to an academic headache clinic. Methods: This is a retrospective cohort study. We used an electronic medical record to look for all patients seen at the Mayo Clinic Florida Headache Center and EDS Clinic between 2019 and 2025 with a diagnosis of hEDS or HSD and neuroimaging of both the intracranial and cervical arteries. Results: There were 103 patients who met the inclusion criteria. There was no statistically significant difference between hEDS and HSD patients in developing cerebral/cervical arterial anomalies. Of the sample, 95% of the hypermobile patients with abnormal neuroimaging also had migraine. A total of eleven (10.7%) patients (hEDS + HSD) were diagnosed with unruptured intracranial aneurysms. Trends included age less than 50 years, small aneurysms in the anterior circulation, and having migraine with aura. Five (4.8%) patients were diagnosed with spontaneous cervical artery dissection with trends for HSD, over the age of 50 years, vertebral artery involvement and a history of migraine without aura. Six (5.8%) patients were diagnosed with fibromuscular dysplasia with trends for HSD, over the age of 50 years, carotid artery involvement and a history of migraine with aura. Conclusions: This is the first study to identify that patients with the more common type of EDS, HSD and hEDS, and a possible concomitant history of migraine have a heightened risk for the development of unruptured intracranial aneurysms, spontaneous cervical artery dissections, and fibromuscular dysplasia. Our findings suggest the need for targeted screening with intracranial and extracranial arterial imaging for this unique patient population.
Acoramidis has a beneficial effect compared with placebo on change from baseline in NAC ATTR stage at month 30 in patients with ATTR-CM: results from the ATTRibute-CM study
Gillmore, J D, Grogan, M, Sutton, T, Dupont, M, Fine, N M, Bhatt, K, Delgado, D, Chen, C, Tamby, J F, Siddhanti, Suresh , Fox, J C, Fontana, M, Gillmore, Julian D , Gillmore, Julian D. , Grogan, M, Fine, Nowell Mark , Bhatt, Kunal , Delgado, D, Chen, C, Fontana, M

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2740 Get It

Abstract Background The National Amyloidosis Centre (NAC) staging system for transthyretin amyloid cardiomyopathy (ATTR-CM) is used to classify patients into prognostic categories based on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and estimated glomerular filtration rate (eGFR). The NAC staging system has been shown to predict ongoing survival throughout the course of ATTR-CM, with survival progressively decreasing from stage I to stage III. Acoramidis, a highly selective, oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, has recently been approved in Europe and the USA for the treatment of wild-type or variant ATTR-CM in adults. In the phase 3 ATTRibute-CM study, acoramidis treatment was well tolerated and led to a 42% relative risk reduction in the composite of all-cause mortality and recurrent cardiovascular hospitalizations over 30 months compared with placebo (p=0.0005). Purpose To evaluate the ability of acoramidis treatment, as compared with placebo, to stabilize or improve NAC stage after 30 months in participants with ATTR-CM from the ATTRibute-CM study. Methods Participants in ATTRibute-CM were randomized 2:1 to receive acoramidis or placebo for 30 months. Efficacy analyses were conducted in the modified intention-to-treat population, which consisted of all randomized participants who had received at least one dose of acoramidis or placebo, had at least one efficacy evaluation after baseline and had a baseline eGFR ≥30 mL/min/1.73 m2. NAC stage at baseline and Month 30 was assessed. Changes from baseline to Month 30 were categorized as "stable", "improved" or "worsened". The "stable" category comprised participants who stayed within the same NAC stage at baseline and Month 30. The "improved" category comprised participants who moved from a higher NAC stage at baseline to a lower stage at Month 30. The "worsened or missing" category comprised participants who moved from a lower NAC stage at baseline to a higher stage at Month 30 and participants whose Month 30 NAC stage was missing. The change in NAC stage was compared between treatment groups using a stratified Cochran-Mantel-Haenszel test with stratification factors of genotype, NT-proBNP level and eGFR as recorded in the interactive voice/web response system at randomization. Results Overall, 611 participants were analysed (acoramidis: n=409; placebo: n=202). Baseline characteristics were comparable between treatment groups. Most participants had NAC stage I at baseline (acoramidis: 58.9%; placebo: 59.4%; Table). At Month 30, NAC stage remained stable or improved in 52.1% of acoramidis participants compared with 43.1% of placebo participants (p=0.0351; Figure). Conclusions Acoramidis treatment resulted in a greater proportion of participants whose NAC stage improved or remained stable at Month 30 compared with placebo, indicating better stabilization of their disease.